Hi Chirley,
Neupogen (G-CSF) has always been suspected of increasing the risk for AML. Many studies on MDS patients have showed that there is no increased risk for AML transformation
:
http://www.ncbi.nlm.nih.gov/pubmed/1...ubmed_RVDocSum
Other studies have showed that Neupogen in cancer patients with neutropenia after chemo there is a risk for worse disease:
http://www.oncologystat.com/news-and...ndrome_US.html
I have to take Neupogen 2 injections/week since neutropenic fever Sept 2007 and hope for the best.
Vidaza is perhaps a better drug for most MDS patients than Revlimid bur your doctor is wrong telling you that you belong to the high risk group only because 2 cellines are affected. There are many systems for classification of MDS and one of them you look at blastcells in the bone marrow, chromosome aberrations and number of cytopenias (few cells) (slide 8).
http://www.ebmt.org/ebmt_2009_slide_bank/209.pdf
If you have less than 5 % blast cells in the bone marrow and no chromosome aberrations you belong to the low risk group
.
Kind regards
Birgitta-A